http://www.aktiencheck.de aktiencheck.de aktiencheck.de Tue, 28 Apr 2026 00:05:41 +0200 2 http://www.aktiencheck.de/forum/MMJ_Group_Holding-A40Y68-t573830 http://www.aktiencheck.de/forum/MMJ_Group_Holding-A40Y68-t573830 Beteiligung, MMJ Group Holdings Ltd (ASX:MMJ, OTC:MMJJF) has completed an investment of A$1 million in the unlisted Valo Therapeutics Oy, as part of a total pre-initial public offering (IPO) equity financing of around US$13 million. The Finland-based immunotherapy company that is developing antigen-coated oncolytic viruses and vaccine vectors as therapeutic vaccines against cancer and infectious diseases, is preparing for an IPO in 2022. MMJ's investment was made from the company existing cash reserves. Investment strategy MMJ Group chair Peter Wall said: “The investment in Valo demonstrates MMJ’s expertise to secure a private negotiated investment in unlisted businesses, which are not generally available to Australian retail and institutional investors. “Valo represents the continued deployment of funds in accordance with its investment strategy following the broadening of MMJ’s investment mandate in 2020.” Validate PeptiCRADd platform Valo Therapeutics CEO Paul Higham said: ” [<a href="http://www.aktiencheck.de/forum/MMJ_Group_Holding-A40Y68-t573830">mehr</a>]